XPAR
GNRO
Market cap1mUSD
Jan 22, Last price
0.03EUR
Name
Geneuro SA
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
342.90%
Rev. gr., 5y
30.91%
Revenues
0k
Net income
-15m
L+20.96%
CFO
-10m
L-22.38%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
GeNeuro SA is a clinical-stage biopharmaceutical company focused on discovering and advancing therapies for neurodegenerative and autoimmune disorders. Its flagship therapeutic, temelimab, a monoclonal antibody, has successfully completed a Phase IIb clinical trial for multiple sclerosis. This same antibody is currently undergoing Phase IIa studies for type 1 diabetes and has entered Phase I trials for chronic inflammatory demyelinating polyneuropathy. The company actively participates in research and development collaborations, including an agreement with The National Institute of Neurological Disorders and Stroke to develop novel antibody treatments for amyotrophic lateral sclerosis, and partnerships with various academic centers researching inflammatory psychosis. Additionally, GeNeuro holds research collaborations with the International Center for Infectiology Research and Northwestern University, investigating the human endogenous retrovirus W envelope protein (HERV-W ENV) in long-haul COVID patients. Founded in 2006, GeNeuro SA's headquarters are located in Plan-les-Ouates, Switzerland.
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||
Revenues | ||||||||
Cost of revenue | ||||||||
Unusual Expense (Income) | ||||||||
NOPBT | ||||||||
NOPBT Margin | ||||||||
Operating Taxes | ||||||||
Tax Rate | ||||||||
NOPAT | ||||||||
Net income | ||||||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | ||||||||
BB yield | ||||||||
| Debt | ||||||||
Debt current | ||||||||
Long-term debt | ||||||||
Deferred revenue | ||||||||
Other long-term liabilities | ||||||||
Net debt | ||||||||
| Cash flow | ||||||||
Cash from operating activities | ||||||||
CAPEX | ||||||||
Cash from investing activities | ||||||||
Cash from financing activities | ||||||||
FCF | ||||||||
| Balance | ||||||||
Cash | ||||||||
Long term investments | ||||||||
Excess cash | ||||||||
Stockholders' equity | ||||||||
Invested Capital | ||||||||
ROIC | ||||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | ||||||||
Price | ||||||||
Market cap | ||||||||
EV | ||||||||
EBITDA | ||||||||
EV/EBITDA | ||||||||
Interest | ||||||||
Interest/NOPBT | ||||||||